knowledge -WSS

knowledge

author：comprehensive 2025-09-28 01:16:37 - browse：54

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： When prostate cancer spreads, where it goes matters

explore

WSS

Glen Campbell's doctor discusses his public struggle with Alzheimer's

National panel will explore requiring free Covid tests

Cytokinetics CEO stresses company can launch heart drug on its own

Mitch McConnell episode has important public health takeaway

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Vertex non

leisure time

knowledge

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Pence says 'crackpot lawyers' told Trump what he wanted to hear

In age of alternative facts, a scholarly course on calling out crap

The high personal cost of affirmative action for Black doctors

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Sage hopes for a blockbuster in antidepressant now before FDA

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

EQRx, failed developer of low

Drug repurposing or repositioning? The language matters

Bird flu: Don't repeat Covid's 'health versus the economy' framing

knowledge

New safety details link Apellis eye drug to rare cases of blindness

With measles on the rise, a personal story of a devastating disease

Mega Millions pot grows to $1.25 billion after no winner

Military medical care influenced by rank and race, new study finds

No plane should take off without an EpiPen onboard

What to expect as Trump is arraigned on his Jan 6. indictment

entertainment

Wikipedia

explore

explore